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Abstract
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Recent advances have permitted successful therapeutic targeting of the immune system in head
and neck squamous cell carcinoma (HNSCC). These new immunotherapeutic targets and agents
are being rapidly adopted by the oncologic community and hold considerable promise. The
National Cancer Institute sponsored a Clinical Trials Planning Meeting to address the issue of how
to further investigate the use of immunotherapy in patients with HNSCC. The goals of the meeting
were to consider phase 2 or 3 trial designs primarily in 3 different patient populations: those with
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previously untreated, human papillomavirus-initiated oropharyngeal cancers; those with
previously untreated, human papillomavirus-negative HNSCC; and those with recurrent/metastatic
HNSCC. In addition, a separate committee was formed to develop integrative biomarkers for the
clinical trials. The meeting started with an overview of key immune components and principles
related to HNSCC, including immunosurveillance and immune escape. Four clinical trial concepts
were developed at the meeting integrating different immunotherapies with existing standards of
care. These designs were presented for implementation by the head and neck committees of the
National Cancer Institute-funded National Clinical Trials Network. This article summarizes the
proceedings of this Clinical Trials Planning Meeting, the purpose of which was to facilitate the
rigorous development and design of randomized phase 2 and 3 immunotherapeutic trials in
patients with HNSCC. Although reviews usually are published immediately after the meeting is
held, this report is unique because there are now tangible clinical trial designs that have been
funded and put into practice and the studies are being activated to accrual.
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The objective of cancer immunotherapy is to reactivate the immune system to target
malignant cells, and it has been demonstrating recent clinical efficacy in many cancer types.1
Derangements in the immune system or alterations in the transformed cells may allow
immune escape, which then enables the cancer to manifest. Immunomodulatory therapies
that overcome immune suppressive signals in patients with Head and Neck Squamous Cell
Carcinoma (HNSCC) have therapeutic promise.2 The recent clinical efficacy of US Food
and Drug Administration (FDA)-approved monoclonal antibodies (MoAbs) targeting
immune checkpoint receptors, including anticytotoxic T-lymphocyte antigen 4 (antiCTLA-4) and anti-programmed cell death protein 1 (anti-PD-1), provided further potential
for patient benefit as positive clinical data emerge. This led to the approval by the National
Cancer Institute (NCI) of a proposal to convene a group of experts focused on developing
immunotherapies rationally and integrating this novel modality into conventional
radiotherapy (RT), chemotherapy, and surgical oncologic therapies.

Author Manuscript

The meeting (which was held November 9–10, 2014 at the NCI Clinical Center in Bethesda,
MD) began with a series of scientific overview presentations focused on the mechanisms of
immune escape in HNSCC, as well as different targets, classes of agents, and information
gained from immunotherapy in other diseases such as melanoma and lung and renal cell
carcinoma. The concept was established that to establish effective immunotherapies,
understanding the different pathways of tumor immune evasion is necessary. The profound
although apparently selective immunosuppression in HNSCC ranges from lymphopenia, to
altered secretion of normal cytokines and inflammatory signaling pathways, to aberrant
skewing of cellular immunity, abetted by suppressive populations such as CD4-positive
regulatory T cells (Treg), macrophages, and myeloid-derived suppressor cells (MDSCs).
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Today, the most widely used form of cancer immunotherapy is MoAb therapy,3 including
tumor antigen (TA)-targeted MoAbs, cytokine-targeted MoAbs, tumor necrosis factor
receptor (TNFR) family costimulatory targeted MoAbs, and immune checkpoint-targeted
MoAbs (Table 1). To our knowledge, the best studied FDA-approved agent for HNSCC is
cetuximab, a mouse-human chimeric immunoglobulin (Ig) G1 antiepidermal growth factor
receptor (EGFR) MoAb.4,5 Anti-EGFR MoAbs can mediate antigen-specific immune
responses through direct killing via natural killer (NK) cell or monocytes lysis or tumor
phagocytosis and subsequent antigen processing. In addition to extensive clinical and
correlative immune response data using cetuximab, MEHD7945A, an antihuman epidermal
growth factor receptor 3 (HER3)/EGFR human MoAb targeting HER3 and EGFR, is
currently being tested in a phase 1/2 clinical trials for HNSCC (ClinicalTrials.gov identifiers
NCT01577173 and NCT01911598). Enhancing the secondary immune response to TAtargeted MoAbs by combination with other immune-targeted therapies is a particularly
appealing approach for patients with HNSCC, given that cetuximab is a standard, FDAapproved agent in those with locally advanced or recurrent/metastatic (R/M) disease.
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Immune checkpoints and costimulatory receptors in HNSCC—Costimulatory
molecules modify T-cell activation, and the duration and extent of immune responses is
regulated by coinhibitory pathways (called “immune checkpoints”) that prevent excessive
autoimmunity. Immune checkpoints can be manipulated as a mechanism of tumor immune
evasion.6 Examples include CTLA-4 and its ligands CD80 and CD86 and PD-1 and its
ligands PD-L1 and PD-L2. Blocking anti-CTLA-4 MoAb therapy results in the rejection of
syngeneic murine cancers.7 An anti-CTLA-4 MoAb, ipilimumab, demonstrated clinical
benefit and was approved by the FDA in 2011 for patients with metastatic melanoma.8
Tremelimumab also targets CTLA-4 and currently is under investigation in patients with
HNSCC. More recently, anti-PD-1 or PD-L1 MoAbs have demonstrated clinical efficacy,
either alone9–11 or in combination with ipilimumab,12 including in patients with
HNSCC.13,14
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Evasion of antitumor immunity by HNSCC occurs by high tumor expression of PD-L1
and/or tumor immune infiltration by PD-1-positive T lymphocytes.15 PD-L1 is expressed in
50% to 60% of HNSCC,16 and tumor infiltration by PD-1-positive regulatory T cells (Treg)
may be more common for patients with human papillomavirus (HPV)-positive compared
with HPV-negative HNSCC.17 Indeed, membrane and/or intracytoplasmic PD-L1 expression
is common in both types of HNSCC.18 Importantly, these studies also demonstrated that
expression of PD-L1 can be induced by interferon gamma (IFN-γ), suggesting that the
tumor microenvironment (TME) dictates tumor expression of PD-L1 and that measurement
of PD-L1 at a single time point or location may not accurately reflect the natural history of
its expression.19 Badoual et al reported tumor infiltration by PD-1-positive, CD8-positive,
and PD-1-positive and CD4-positive lymphocytes was more common among patients with
HPV-positive than HPV-negative HNSCC. In 33 of 64 cases of HNSCC (52%), high levels
of PD-L1 expression were observed, but there was no association between PD-L1 expression
and tumor HPV status.17 A higher expression of immune checkpoint receptors (CTLA-4 and
PD-1) in intratumoral Treg cells compared with on matched peripheral blood samples has
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been observed among patients with HNSCC.20 These data strongly support a role for PD-1
inhibition in the treatment of patients with HNSCC. Seiwert et al recently reported
promising preliminary efficacy associated with the anti-PD-1 MoAb pembrolizumab in a
large (>130 patients) phase 1b cohort with refractory, R/M HNSCC, as measured by
response rate and overall survival (OS).14 In a CheckMate 141 study, a randomized phase 3
trial of nivolumab versus single-agent chemotherapy, an OS benefit was observed,21 with a
30% improvement in OS and a doubling of patients alive at 1 year, indicating that FDA
approval for this agent is imminent. Pembrolizumab was approved by the FDA in August
2016 for the treatment of HNSCC. Anti-PD-1 MoAbs also are being tested in various novel
combinations in the phase 1 setting, such as nivolumab plus an agonistic anti-CD137 MoAb
(urelumab; ClinicalTrials.gov identifier NCT02253992) and nivolumab plus an antilymphocyte-activation protein 3 (LAG-3) MoAb (ClinicalTrials.gov identifier
NCT01968109), as well as cetuximab plus urelumab (ClinicalTrials.gov identifier
NCT02110082).
Other checkpoint receptors (Table 2) such as LAG-3 or the killer-cell immunoglobulin-like
receptors, which interact with major histocompatibility complex (MHC) molecules to
regulate immune responses, currently are being investigated in combination with anti-PD-1.
Ongoing pharmaceutical-sponsored trials include the investigation of an anti-killer-cell
immunoglobulin-like receptor MoAb in combination with the anti-CTLA-4 MoAb
ipilimumab (ClinicalTrials.gov identifier NCT01750580) or the anti-PD-1 MoAb nivolumab
(ClinicalTrials.gov identifier NCT01714739).
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In addition to blocking negative regulatory receptors on effector lymphocytes, another
strategy has emerged to enhance and trigger positive, costimulatory signals using agonistic
MoAbs and small molecules. To our knowledge to date, the investigation of TNFR-targeting
MoAbs in clinical trials for HNSCC currently is in phase 1. Because of the important
costimulatory pathways for immune cell activation, substances such as CP-870,893 (Pfizer),
an IgG2 CD40 agonist; OX40 MoAb (AstraZeneca/Medimmune), an IgG2 OX40 agonist; or
urelumab (Bristol-Myers Squibb), an IgG4 CD137 agonist, have been investigated with
cetuximab or with nivolumab in clinical trials.22 Toll-like receptor agonists induce the
maturation and cross-priming of dendritic cells (DCs), and have been shown to induce NK
cell-dependent lysis of tumor cells in combination with TA-targeted MoAbs such as the antiEGFR MoAb cetuximab.23 The toll-like receptor 8 -agonist motolimod currently is under
investigation in combination with cetuximab-based therapy in patients with HNSCC
(ClinicalTrials.gov NCT02124850 and NCT01334177).
Integration of Immunotherapy into Clinically Defined Patient Groups
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The NCI-funded Clinical Trials Planning Meeting facilitated the rational design of
combinations of immunotherapies for phase 2 and 3 randomized trials in patients with
HNSCC. The meeting was organized around 4 breakout groups. Three groups were focused
on specific biologic subsets of HNSCC: HPV-positive, previously untreated, locally
advanced (PULA) disease; HPV-negative PULA disease; and R/M HNSCC. A fourth group
of scientists focused on correlative tissue and imaging biomarkers. After developing
harmonized recommendations for biomarker and imaging correlatives, this fourth group’s
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proposed correlative studies and assays were integrated into the discussions and trial designs
emanating from the 3 therapeutic cohort groups.
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Recurrent/metastatic HNSCC—Patients with R/M HNSCC have a particularly poor
prognosis, with a median OS of approximately 10 months. Akin to what is observed in the
setting of primary disease, patients with HPV-positive R/M tumors enjoy improved
outcomes, with a 2-year OS rate of approximately 55% versus 28% for their HPV-negative
counterparts.24 For nearly 3 decades, the cornerstone of first-line palliative systemic therapy
has been cisplatin,25 frequently combined with 5-fluorouracil or a taxane due to increased
response rates (albeit with no conclusive evidence of superior OS compared with cisplatin
monotherapy).26 In 2006, cetuximab became the first FDA-approved, TA-targeted MoAb for
patients with HNSCC. When combined with platinum and 5-fluorouracil, cetuximab
increased both progression-free survival and OS in patients with R/M disease (the so-called
“EXTREME” regimen).27 Cetuximab also is indicated as monotherapy in patients with R/
M, platinum-refractory HNSCC.28 Unfortunately, these treatments generally are not curative
and to the best of our knowledge no established therapies exist for the cetuximab-refractory
population, which is an area of profound unmet need.
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In response to this therapeutic void, there has been a proliferation of clinical trials testing
immunotherapeutic MoAbs in patients with R/M disease (Table 2). For example, a phase 1b
clinical trial investigated the anti-PD-1 MoAb pembrolizumab (MK-3475; Merck) and
yielded response rates (partial response/complete response) of approximately 20%.
Importantly, and contrary to existing data with standard chemotherapeutics, response rates
were found to be similar in both HPV-positive and HPV-negative cohorts. These early
efficacy data were substantiated in the recent phase 3 trial, CheckMate 141, which compared
single-agent nivolumab with investigator’s choice single-agent therapy. This trial closed
early when an OS benefit was shown (360 patients) (ClinicalTrials.gov identifier
NCT02105636), and the results will be reported in the near future.21
Importantly, these promising results are not limited to anti-PD-1, as anti-PD-L1 also has
demonstrated comparable efficacy in a phase 1 trial. The success of this initial study
prompted the design of a phase 3 trial evaluating MEDI4736 alone or in combination with
the anti-CTLA-4 MoAb tremelimumab compared with standard of care, second-line agents
(720 patients) (ClinicalTrials.gov identifier NCT02369874). Stratification by PD-L1
expression status is planned.
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Based on the positive outcomes found to be associated with the use of checkpoint inhibition
after first-line failure, a recently initiated phase 3 trial will now move PD-1 targeting forward
into the first-line setting for patients with R/M disease. Specifically, this trial will compare
the anti-PD-1 MoAb pembrolizumab alone or in combination with platinum/5-fluorouracil
versus the EXTREME regimen (600 patients) (ClinicalTrials.gov identifier NCT02358031).
Despite the excitement generated by the evaluation of checkpoint inhibition as first-line
therapy in the R/M setting, the uncomfortable reality is that a large number of these treated
patients will likely continue to die of their disease. Indeed, it was this reality that prompted
the formation of the R/M disease working group, which was charged with the development
of clinical trials to meet the needs of patients whose disease is refractory to existing therapy.
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Although many trials were proposed for development, the clinical trial eventually adopted
by the recurrent metastatic working group was the brainchild of the late Dr. Holbrook Kohrt.
This trial design was premised on 2 fundamental considerations: first, that defined
cosignaling pathways can be induced on Fc γ receptor (FcγR)-bearing immune effector
cells through FcγR engagement by the aggregated Fc fragments of immobilized
antibodies29; and second, that blockade of select immunologic checkpoints (eg, PD-1/PDL115,30 in combination with the stimulation of defined cosignaling molecules (eg, CD137
[4-1BB]) have synergistic antitumor activity. His laboratory and that of one of the coauthors
(R.L.F.) have demonstrated that engagement of CD16 on the surface of NK cells induced
high levels of CD137 expression.31,32 Subsequent studies demonstrated that CD137 could be
induced on NK cells by the Fc fragments of antibodies bound to the tumor cell surface and
that engagement of CD137 on these NK cells33,34 or by DC35 by agonistic antibodies could
potentiate their antitumor activity.32
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Based on these data, the working group proposed a prospective randomized clinical trial
design with 3 arms. In this schema, all groups would receive cetuximab “induction” on day
1, followed by additional doses on days 8 and 15. Importantly, the purpose of cetuximab
administration in this setting was not simply to mediate killing of EGFR-expressing tumors
but also to induce CD137 expression on the surface of infiltrating NK cells. On study day 2,
patients in group 1 would receive an agonistic MoAb against CD137, patients in group 2
would receive anti-PD-1 or anti-PD-L1, and patients in group 3 would receive a combination
of anti-CD137/PD-1 or PD-L1. Each cycle was designed to last 21 days and response to
treatment would be assessed at the end of 12 cycles. The 2 primary endpoints were safety
and 6-month progression-free survival. Successful completion of the study would enable
determination of: 1) the ability of cetuximab to induce CD137 on circulating NK cells in
patients with HNSCC; and 2) the ability of anti-CD137/ PD-1 or PD-L1 to improve survival
in comparison with either agent alone. A limitation of the design might be the inability to
include a cetuximabonly cohort, based on feasibility considerations, as well the lack of
toxicity or efficacy data for combinations with urelumab (agonistic anti-CD137).
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Role of immunity in response to chemoradiotherapy—Cytotoxic cancer therapies
alone are aimed at tumor eradication through the direct killing of cancer cells. However, full
and sustained clinical remission is elusive for many patients receiving standard-of-care
treatments. Striking clinical observations in recent years have indicated that patients
harboring certain malignancies achieved higher clinical benefit with immunotherapy if
previously treated with certain anticancer therapies. These observations are now supported
by accumulating evidence demonstrating that conventional and emerging anticancer
therapies modulate the tumor to induce a more immunostimulatory milieu.36,37
Immunogenic cell death and immunogenic modulation by chemoradiotherapy
—Cancer therapeutic regimens trigger cancer cell death while stimulating endogenous
immune responses against the tumor, termed “immunogenic cell death.”37,38 The cardinal
signs of immunogenic cell death are 1) calreticulin exposure on the surface of dying cells; 2)
the release of HMGB1; and 3) the release of ATP, which acts on DCs to facilitate the
presentation of TAs to the immune system. Tumor cells that survive therapy have been
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shown to alter their biology to render them more sensitive to immune-mediated killing,
termed “immunogenic modulation.”36,39 Immunogenic modulation encompasses a spectrum
of molecular alterations in the biology of the cancer cell that independently or collectively
make the tumor more amenable to cytotoxic T-lymphocyte (CTL)– mediated destruction.
These include: 1) downregulation of antiapoptotic/survival genes; 2) modulation of antigenprocessing machinery components; and 3) calreticulin translocation to the cell surface of the
tumor. One can envision that these immunogenic consequences of anticancer therapy,
ranging from immunogenic cell death to immunogenic modulation, can be harnessed to
achieve synergy with immunotherapy regimens, therefore maximizing the clinical benefit for
patients with HNSCC receiving combination therapy.
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If immunotherapies are to be used early in the disease process, they would most likely need
to be used in combination with chemotherapeutic agents. Although counterintuitive, it has
recently been shown that immunotherapy may not only be compatible with chemotherapy,
but also actually may be synergistic. Various chemotherapy agents have been shown to
induce immunogenic modulation in tumors of diverse origin by upregulating immunerelevant proteins on the surface of cancer cells, including TAs, calreticulin, adhesion
molecules such as intercellular adhesion molecule 1 (ICAM-1), and MHC class I proteins.
These phenotypic changes translated into increased murine and/or human tumor sensitivity
to CTL-mediated lysis in vitro after exposure to sublethal doses of chemotherapy with
cisplatin,40 taxanes,41 or cisplatin plus vinorelbine.42 These preclinical findings and others
have translated into various hypothesis-generating clinical trials. Several points are
important when considering the use of chemotherapy with immunotherapy: 1) the combined
use of immunotherapy and chemotherapy early in the disease process should not be
confused with the use of immunotherapy after multiple regimens of different
chemotherapeutic agents in the advanced disease setting, in which the immune system
would most likely be impaired; 2) not all chemotherapeutic agents will be synergistic with
immunotherapy; and 3) the dose and scheduling of immunotherapy when used with
chemotherapy may be extremely important, and after immune function may guide trial
optimization.
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Checkpoint inhibitors and radiotherapy—Radiotherapy (RT) can induce a continuum
of immunogenic alterations in dying and/or surviving tumor cells. Lethal irradiation has
been reported to induce immunogenic cell death. Although immune responses in patients
with cancer undergoing RT alone are often weak and rarely translate into protective
immunity, the immunogenic effects of RT can be exploited to promote synergistic clinical
benefit for patients receiving combination regimens with immunotherapy.43,44 It has been
demonstrated that the use of relatively low doses of external-beam radiation, insufficient to
kill tumors, induces immunogenic modulation, thereby altering those tumor cells to render
them more susceptible to T cell–mediated lysis.36,45 These findings have translated into
promising clinical benefits for patients with HNSCC who are receiving RT plus
immunotherapy. Of importance, it has been shown specifically with an in vitro model of
HNSCC that treatment with RT and cisplatin chemotherapy can lead to synergistic
sensitivity to antigen-specific T-cell killing.46
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Previously untreated, locally advanced, HPV-positive oropharyngeal cancer: In addition
to the classic risk factors of tobacco and alcohol, HPV type 16 now represents a primary
cause of HNSCC in North America and Europe.47,48 HPV status and pack-years of tobacco
exposure are the major determinants of survival among patients with HNSCC, followed by
lymph node stage.49 Based on these 3 prognostic factors, patients with HNSCC can be
classified into 3 risk groups having a low, intermediate, or high risk of death. This clinical
risk classification has framed national clinical trial priorities in PULA HNSCC. Specifically,
deintensification strategies currently are being tested in patients with low-risk, HPV-positive
HNSCC whereas intensification strategies represent the major unmet need for individuals
with high-risk HPV-negative and intermediate-risk HPV-positive disease.50–52
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For patients with HPV-positive, PULA HNSCC, working group 1 (Fig. 1) identified 2
priorities: 1) more targeted HPV-specific therapy taking advantage of unique non-self, viral
TAs present within HPV-positive tumors; and 2) to determine the sequencing and optimal
chemoradiotherapy (CRT) regimens that do not inhibit immunotherapeutic efficacy (Fig. 1).
Currently, immunotherapeutic trials open or currently in development include eliminating
systemic cytotoxic chemotherapy by combining intensity-modulated radiotherapy with
cetuximab and the anti-CTLA-4 MoAb ipilimumab (ClinicalTrials.gov identifier
NCT01935921), in which the overlap of ipilimumab exposure begins at week 5 of treatment
with cetuximab and RT. In addition, patients with “intermediate-risk,” HPV-positive and
“high-risk,” HPV-negative disease will be treated with concurrent, weekly CRT with
cisplatin with an anti-PD-1 MoAb, a natural “add-on” strategy that currently is in
development (Radiation Therapy Oncology Group [RTOG] Foundation trial 3504) and will
open to enrollment in the near future.
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First-generation “deintensification” clinical trials for patients with HPV-positive PULA
disease enrolled patients with both good and intermediate risk, with the goal of reducing
chemotherapy and/or RT doses (fields) (Eastern Cooperative Oncology Group [ECOG]
1308, RTOG 1016). As clinical risk stratification evolves, second-generation
deintensification trials are selecting only good-risk patients (HN002). New trials are needed
for patients with intermediate-risk, worse-prognosis, HPV-positive disease. The proposed
trial aims to harness novel systemic immunotherapy and use the unique viral antigens (the
oncogenes E6 and E7) expressed in HPV-positive HNSCC to improve disease-free survival
(DFS) as well as make an impact on the burden of uncommon, although lethal, distant
metastatic disease for patients with intermediate-risk, HPV-positive PULA disease (those
with T3/4 disease, those with N2c/N3 disease, > 10 pack-year smokers, and HPV-positive
patients52. The proposed concept (Fig. 1) would compare anti-PD-1 plus cisplatin CRT with
the combination of anti-PD-1/CRT plus HPV-specific E6/E7 vaccination. Several vaccines
currently are available and have been tested in phase 1 trials for cervical and other HPVpositive cancers, and include peptide plus adjuvant, DNA-based or Listerolysin O-based
vectors. Collaboration between a cooperative group and 1 or 2 pharmaceutical company
sponsors is likely to be necessary. A neoadjuvant (pre-CRT) phase of 1 to 2 doses of vaccine
with or without an anti-PD-1 MoAb was strongly considered because the timing and
sequence of HPV-specific T-cell expansion vis-a-vis cytotoxic CRT, which may inhibit
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lymphocyte expansion, is undetermined. This approach, although more cumbersome, also
would permit the correlation of dynamic tumor and peripheral immune biomarkers with
clinical outcomes.
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PULA HPV-negative HNSCC—Approximately 80% of HNSCC diagnoses worldwide
remain secondary to environmental carcinogens, including tobacco and alcohol. Recent
improvements in 5-year OS for the HNSCC population as a whole are largely attributable to
the epidemic of good-risk, HPV-positive HNSCC, which involves younger and lower-risk
populations.48 The OS for patients with high-risk, PULA, HPV-negative HNSCC has
improved only marginally within the last 20 years due to the incorporation of concurrent
cisplatin in curative-intent paradigms. The current standard for the nonsurgical management
of patients with PULA, HPV-negative, HNSCC is concurrent cisplatin and CRT, which
improved OS, DFS, and locoregional control compared with RT alone in the sentinel
Intergroup 0126 trial, a trial that was populated before the HPV epidemic.53,54 Standards for
the adjuvant management of patients with PULA, HPV-negative, HNSCC are determined by
pathologic risk. Specifically, for patients who demonstrated ≥1 high-risk pathologic features,
including a positive surgical margin or extracapsular lymph node extension, concurrent
cisplatin and RT appeared to provide a clinical benefit compared with RT alone in the
landmark phase 3 European Organisation for Research and Treatment of Cancer (EORTC)
22931 and RTOG 9501 trials.55,56 Despite this advance, patients with high-risk, HPVnegative disease have a 3-year DFS rate of only 30% to 50%.55–57 Although locoregional
control and OS are improved with concurrent cisplatin and RT, a meta-analysis indicated
disappointing local and distant failure rates of 50% and 15%, respectively, and an absolute
survival benefit of only 6.5% compared with RT alone.58 Poor outcomes persist despite
intensification with altered fractionation,59 multidrug induction,60 or EGFR-targeted
MoAbs.61
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For HPV-negative patients, new intensification approaches represent a major unmet clinical
need. The PULA HPV-negative working group initially discussed 2 clinical trial paradigms
for patients with high-risk disease: 1) the integration of immunotherapy into definitive
cisplatin CRT; and 2) the integration of immunotherapy into trimodality therapy for highrisk patients (Fig. 2). Ultimately, the recommended focus on the trimodality model
capitalized on 3 opportunities. First, the accessibility of the tumor and TME for serial
assessment. The natural anatomy of HNSCC presents specific accessibility of the primary
tumor and TME for serial biopsy. In the proposed trial, the incorporation of primary surgery
permits a “window of opportunity” for exposure to a specific immunotherapy between
diagnostic biopsy and planned surgery, thereby facilitating pharmacodynamic evaluation of
the tumor and TME responses in paired specimens. The second opportunity is the
integration of immunotherapy with RT (Figure 3). Ionizing RT induces adaptive immune
responses via 3 broad mechanisms that could be synergistic with immunotherapy, including
release of TAs for processing and presentation, upregulation of stimulatory chemokines
within the TME, and increased tumoral expression of TA and MHC.62 The third opportunity
is the integration of immunotherapy with cisplatin. Although cytotoxic chemotherapy is
conventionally viewed as immunosuppressive, cisplatin also demonstrates stimulatory
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effects, including upregulation of MHC, recruitment and proliferation of effector cells,
enhanced cytolytic activity of effector cells, and downregulation of MDSCs and Treg cells.40
The immune checkpoint inhibitors, antagonizing the CTLA-4 or PD-1 pathways, were
considered to be of greatest priority for development in the HPV-negative PULA population.
First, environmentally induced HNSCC demonstrates a high mutational burden.63,64
Mutational load, as well as the presence of highly immunogenic neoantigens, has been
correlated with response to immune checkpoint inhibitors in other solid tumors.65,66 Second,
RT dynamically upregulates PD-L1 on both tumor and MDSCs, thereby reducing the
adaptive response and theoretically facilitating future disease recurrence. In 2 syngeneic
preclinical models, concurrent PD-L1 blockade and RT were found to be synergistic in
controlling tumor growth, and generated prolonged protective T-cell immunity, as
demonstrated by subsequent abscopal effect.67
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The central hypothesis of the proposed randomized phase 2 trial considers whether adding
immunotherapy to CRT with adjuvant cisplatin increases the DFS in patients with high-risk,
resected, PULA, HPV-negative HNSCC. In this trial design, the window of monotherapeutic
exposure before definitive surgery creates a unique opportunity with which to study placebocontrolled, pretreatment and posttreatment tumor and blood specimens to isolate immune
mechanisms, and to correlate baseline and pharmacodynamic biomarkers with 2-year DFS.
We propose to evaluate baseline and changes in immune-inflammatory biomarkers in both
tumor and the TME, and to correlate these biomarkers with the 2-year DFS. Markers will
include immunohistochemistry (IHC) or immunofluorescence (IF) for CD3, CD8, CD45RO,
CD4/forkhead box P3 (FOXP3), PD-L1, and Ki-67; flow cytometry for tumor-infiltrating
lymphocytes and MDSC subsets; T-cell activation panel and memory subsets; changes in Tcell receptor (TCR) clonality; and whole exome sequencing for peptide-encoding tumor
neoantigens.
Immunotherapy Trial Biomarkers and Unique HNSCC Patient Specimen Considerations
From tumor samples, IHC/IF detection of immune markers provide a measure of baseline
immune cell infiltration, phenotype, localization, and “inflammation,” sometimes referred to
as an “immunoscore” because this has been shown to have prognostic and predictive
capacity for immunotherapy in other diseases, including colorectal cancer.68–71 These
markers include CD3, CD8, CD45RO, CD4/FOXP3, and perhaps PDL-1 (on tumors vs
myeloid cells). The biomarkers working group recommended combining these basic stains
for infiltrate with the specific targets in a proposed trial (PD-1, CTLA-4, OX-40, TIM-3,
LAG-3, CD40, etc). Multiplexed IF makes testing multiple parameters more feasible.72
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From fresh frozen tissue, the following genomic or signaling assays were recommended
(Table 3): 1) RNA analysis to determine the IFN-γ gene signature; 2) PD-L1 and PD-L2
IHC staining on tumor and infiltration myeloid inflammatory cells; 3) RNA sequencing (to
include the inhibitory/costimulation/exhaustion molecules targeted); 4) TCR diversity (as a
measure of TCR skewing and clonality of the infiltrated T-cell response); and 5) any trialspecific pathways (eg, phospho-SMAD in the setting of a transforming growth factor β
[TGF-β] inhibitor study proposed at the CTPM).
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The above assessments would be performed on all biopsies taken, including the “window”
(neoadjuvant) trials taking advantage of paired pretreatment and posttreatment tumor
specimens in the HPV-negative and the HPV-positive PULA trials. A new biopsy would be
needed for the R/M study (not on primary tumor banked earlier). Some technologies can use
formalin-fixed, paraffin-embedded tissue, which is more easily obtained.
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From peripheral blood samples (ie, ficoll-gradient separated peripheral blood mononuclear
cells [PBMCs]), flow cytometry should accomplish the following: relative quantification of
circulating suppressive MDSCs and Treg cells; T-cell activation panels (eg, inducible
costimulator in CTLA-4 trials and CD69 for general activation); lymphocyte memory
subsets (CD45RO, CCR7 central trafficking); NK cells; and PD-1, CTLA-4, and/or any trial
design-related costimulatory/coinhibitory molecules. Specific intracellular molecules (TGFβ: phospho-STAT) also would be measured. To the best of our knowledge, ECOG/American
College of Radiology Imaging Network and NRG Oncology are not currently collecting and
processing fresh PBMCs for functional and phenotypic studies, and processes,
infrastructure, and funding support would need to be developed for real-time shipping,
processing, and storage to take advantage of the great opportunities in different
immunotherapeutic strategies being used and to maximize the predictive and prognostic as
well as mechanism of action biomarker analyses.
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Antigen-specific cytokine flow cytometry is possible using MHC: peptide multimers or nonhuman leukocyte antigen-restricted overlapping peptide pools: for HPV-positive tumors, E6
and E7 peptide pools (including testing for surface CD4 and CD8) and polyfunctional
intracellular cytokines and effector molecules (IFN-γ, TNF-α, interleukin 2, and
granzymes). For non-HPV tumors, shared tumor antigen peptide pools can be pursued (eg,
p53, survivin) with surface CD4 and CD8, polyfunctional intracellular cytokines, and
effector molecules. Control antigen peptide pools can be used to document and monitor
memory recall responses. Additional cellular blood assays also were considered, including
genomic single-nucleotide polymorphism analysis for possible predictive genomic
biomarkers from PBMC germline DNA. Similarly, transcriptional signatures have been
identified from peripheral blood messenger RNA that may be unbiased and hypothesisgenerating.
From serum, recommended assays include multiplex cytokine analysis (for a comparison of
agents only) and inflammatory molecules (especially for cytokines) as potential mediators of
toxicity (baseline interleukin 17 and CTLA-4 toxicity). Currently, 30 to 60 different analytes
are tested in each small sample.
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Imaging biomarkers are an important correlate in novel prospective trials but this field was
believed to be underdeveloped as a whole in immunotherapy, given several factors. These
include occasional “delayed” or atypical/ mixed responses, which are reflected in immune
response Response Evaluation Criteria In Solid Tumors (RECIST) for R/M disease.73 For
the short term, anti-PD-1 “window” neoadjuvant studies, [18F]fludeoxyglucose-positron
emission tomography/computed tomography before and after 4-week induction may be a
predictor of early response via standardized uptake value measurements, because anatomic
shrinkage may not be observed in the short term. However, infiltrating immune cells may be
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metabolically active, confounding interpretation of increased [18F]fludeoxyglucose avidity
in the TME. The imaging biomarker experts noted that there is no current technology for the
assessment of immune activity and infiltration via imaging, which represents a major unmet
clinical need.
Potential pitfalls and additional considerations exist in these immune biomarker
assessments. For example, there are unanswered technical questions regarding the feasibility
of tumor analysis. For blood, given some limitations in volumes and yields, prioritization is
needed for the different assays. It is assumed that absolute lymphocyte counts, which are a
candidate biomarker for some checkpoint blockade therapies (particularly CTLA-4), are
serially obtained before/during/after in clinical laboratories. Last, stool samples and oral
swabs could be considered for future microbiome studies.
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Conclusions
Cancer immunology is a rapidly evolving field, and only recently have we begun to
understand the complex interaction between cancer and the host immune system. Tumor
cells demonstrate several methods with which to exploit the immune system to help promote
angiogenesis, derive pro-survival and proliferative signals, and induce metastasis and tumor
progression. At the same time, cancers are able to cloak themselves from the immune
system by self-modification and by immunosuppression of the host. Recent results from
clinical trials provide evidence for effective anticancer immunotherapies. Because of the
manifold tumor evasion strategies and hence different response rates for treatments,
combination therapies will be helpful in developing cancer treatments.
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The HNSCC Immunotherapy CTPM was designed to harness these insights and to generate
a better under-standing of several promising immunotherapeutic agents that currently are in
clinical use as well as others currently in development. Four clinical trial concepts emerged
during this important and productive meeting. Great enthusiasm and collaborative effort will
lead to the “hand-off” of these concepts to the head and neck committees of ECOG/
American College of Radiology Imaging Network and NRG Oncology for submission and
review by NCI Cancer Therapy Evaluation Program and the Head and Neck Steering
committee processes. Success will likely depend on the development of industry
collaborations and support. The integration of industry into the open, educational portion of
the meeting was intended to facilitate and enhance these interactions and relationships.
Given the unique features of HNSCC, including tumor accessibility for serial biopsies and
the balance between carcinogen and virally induced cancer subsets, these trials should
provide important information for the field of immunotherapy as a whole.
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Figure 1.

Author Manuscript

Working Group 1. Window immunotherapy biomarker study followed by definitive
chemoradiotherapy (CRT) plus human papillomavirus (HPV) vaccine, anti-programmed
death 1 (PD-1)/PD-ligand 1 axis (PD1/PL1) monoclonal antibody (mAb), or both in patients
with T4 or N3, HPV-positive (+) oropharynx cancer. CT indicates computed tomography;
DDP, cisplatin; Gy, grays; HNSCC, head and neck squamous cell carcinoma; PD-L1,
programmed death-ligand 1; PULA, previously untreated, locally advanced; TME, tumor
microenvironment.

Author Manuscript
Cancer. Author manuscript; available in PMC 2017 November 28.

Bauman et al.

Page 19

Author Manuscript
Author Manuscript
Figure 2.
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Working Group 2. Randomized, phase 2 study of adjuvant cisplatin and radiotherapy with or
without antiprogrammed death-ligand 1 (PD-L1) monoclonal antibody (mAb) in patients
with high-risk, human papillomavirus (HPV)-negative (−) head and neck cancer with
window correlatives. CRT indicates chemoradiotherapy; CT, computed tomography; DFS,
disease-free survival; ECOG, Eastern Cooperative Oncology Group; IMRT, intensitymodulated radiotherapy; PD1/L1, programmed death 1 (PD-1)/PD-ligand 1 axis; TME,
tumor microenvironment.
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Figure 3.
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Working Group 3. A randomized phase 2 study of stereotactic body radiosurgery (SBRT)
plus antiprogrammed death 1 (PD-1)/PD-ligand 1 axis (PD1/L1) monoclonal antibody
(mAb) versus antiprogrammed death-ligand 1 (PD1/L1) mAb alone for oligometastatic head
and neck cancer. Gy indicates grays; HNSCC, head and neck squamous cell carcinoma; IV,
intravenously; q, every; TME, tumor microenvironment.
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Potential Therapeutic Targets in Head & Neck Squamous Cell Carcinoma (HNSCC)
Target

IgG Class

HNSCC Development
Stage

Proposed Mechanism of
Action

Cetuximab (Bristol-Myers Squibb, Eli Lilly)

EGFR antagonist

IgG1

Phase 3/4

Tumor growth inhibition,
cellular immunity

Panitumumab (Amgen)

EGFR antagonist

IgG2

Phase 2/3

Tumor growth inhibition

AV-203 (Aveo)

HER3 antagonist

IgG1

Phase I (monotherapy;
cetuximab combination)

Tumor growth inhibition

Cixutumumab (Eli Lilly)

IGFR antagonist

IgG1

Phase 0–2 (neoadjuvant
monotherapy; cetuximab
combination)

Tumor growth inhibition

VEGF neutralizing Ab

IgG1

Phase 3 (platinum
chemotherapy+/−)

Inhibition of angiogenesis,
impairment of VEGFinduced
immunosuppression

HGF neutralizing Ab

IgG1

Phase 1 (cetuximab
combination; cisplatinRT combination)

Tumor growth inhibition

MEDI0562 (AstraZeneca/Medimmune)

OX40 agonist

IgG2

Phase 1b

Stimulation of cellular
immunity

Urelumab (Bristol-Myers Squibb)

CD137 agonist

IgG4

Phase 1

Stimulation of cellular
immunity

PF-05082566 (Pfizer)

CD137 agonist

IgG2

Phase 1

Stimulation of cellular
immunity

Ipilimumab (Bristol-Myers Squibb)

CTLA-4

IgG1

Phase 1 (cetuximab-RT
combination)

Blockade/depletion of Treg,
enhancement of CTL

Tremelimumab ( AstraZeneca/Medimmune)

CTLA-4

IgG2

Phase 1

Blockade/depletion of Treg,
enhancement of CTL
activity

PD-L1

IgG1

Phase 2

Enhancement of CTL
activity

Pembrolizumab (MK-3475; Merck)

PD-1

IgG4

Phase 1

Enhancement of CTL
activity

Nivolumab (Bristol-Myers Squibb)

PD-1

IgG4

Phase 3

Enhancement of CTL
activity

Drug (Company)
Tumor antigen-targeted MoAbs

Cytokine -targeted MoAbs
Bevacizumab (Genentech)

Author Manuscript

Ficlatuzumab (Aveo)

TNF receptor-targeted MoAbs

Immune checkpoint targeted MoAbs

Author Manuscript

MEDI4736 (AstraZeneca/Medimmune)

Abbreviations: CTL, cytotoxic T-lymphocyte; CTLA-4, cytotoxic T-lymphocyte antigen 4; EGFR, epidermal growth factor receptor; HER3, human
epidermal growth factor receptor 3; HGF, hepatocyte growth factor; HNSCC, head and neck squamous cell carcinoma; IGFR, insulin-like growth
factor receptor; IgG, immunoglobulin G; MoAb, monoclonal antibodies; PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand
1; RT, radiotherapy; Treg, regulatory T cell; TNF, tumor necrosis factor; VEGF, vascular endothelial growth factor.
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Immunotherapeutic Agents
Drug

Mechanism

Enhancing ADCC
IL-12 (NCI)

Cytokine agonist of NK cell activation

IL-15 (NCI)

Cytokine agonist of NK cell activation

VTX-2337

TLR 8 agonist; enhanced DC activation andh IL-12 secretion

Lirilumab (Bristol-Myers Squibb)

Anti-KIR MoAb

1-7F9 (Innate)

Anti-KIR MoAb

Targeting immunosuppressive cytokines
Siltuximab

Anti-IL-6 MoAb

CAT-192

Anti-TGF-β MoAb

T-cell costimulatory agonists

Author Manuscript

CP-870,893 (Pfizer)

CD40 agonist MoAb

OX40 MoAb (AgonOx; Providence Health)

OX40 agonist MoAb

Urelumab (Bristol-Myers Squibb)

CD137 agonist MoAb

PF-05082566 (Pfizer)

CD137 agonist MoAb

IMP321 (Immutep)

Recombinant soluble dimeric LAG-3

T-cell immune checkpoint inhibitors
Ipilimumab (Bristol-Myers Squibb)

Anti-CTLA-4 MoAb

Tremelimumab (AstraZeneca/Medimmune)

Anti-CTLA-4 MoAb

Nivolumab (Bristol-Myers Squibb)

Anti-PD-1 MoAb

Pembrolizumab (Merck)

Anti-PD-1 MoAb

Durvalumab (MEDI-4736 (AstraZeneca/Medimmune)

Anti-PD-L1 MoAb

MPDL3280A (Genentech)

Anti-PD-L1 MoAb

Author Manuscript

MSB0010718C (EMD-Serono)

Anti-PD-L1 MoAb

AUNP12 (peptide) (Pierre Fabre/Aurigene)

Anti-PD-L1 peptide

BMS-986016 (Bristol-Myers Squibb)
INCB024360 (Incyte)

Anti-LAG-3 MoAb
Orally available inhibitor
of indoleamine 2,3-dioxygenase (IDO1)

Abbreviations: ADCC, antibody-dependent cell-mediated cytotoxicity; CTLA-4, cytotoxic T-lymphocyte antigen 4; DC, dendritic cells; IL,
interleukin; KIR, killer inhibitor receptor; LAG-3, lymphocyte-activation protein 3; MoAb, monoclonal antibody; NCI, National Cancer Institute;
NK, natural killer; PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand 1; TGF-β, tumor growth factor-β; TLR, toll-like
receptor.
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Correlative Biomarkers for Cancer Immunotherapy
Tumor

PBMC

Serum

Imaging

Future

Infiltrate: CD3, CD8, CD45RO,
CD4/FOXP3, PD-L1;
frequency, location IHC, IF

Suppressors: Treg, MDSC

Multiplexed circulating
cytokines, chemokines,
growth factors

FDGPET/CT
before and
after 4-wk
induction

Stool/oral swabs for
microbiome

Major checkpoints/
costimulatory (PD-1, CTLA-4,
TIM-3, LAG-3, OX-40, and
CD40)

Effector activation (ICOS,
CD69), effector/memory,
cytotoxicity

Circulating antibodies

NK cells
Ki-67

NK cells
Trial-specific pathways

Author Manuscript

RNA Seq

HPV-positive: virus peptide
pools

TCR diversity

HPV-negative: shared tumor
antigen peptide pools

Trial-specific pathways

Imaging immune response

ALC as SOC

Abbreviations: ALC, acetyl-l-carnitine; CT, computed tomography; CTLA-4, cytotoxic T-lymphocyte antigen 4; FDG-PET, [18F]fludeoxyglucosepositron emission tomography; FOXP3, forkhead box P3; HPV, human papillomavirus; ICOS, inducible costimulator; IF, immunofluorescence;
IHC, immunohistochemistry; LAG-3, lymphocyte-activation protein 3; MDSC, myeloid-derived suppressor cells; NK, natural killer; PBMC,
peripheral blood mononuclear cells; PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand 1; SOC, standard of care; Treg,
regulatory T cells; TCR, T-cell receptor; TIM-3, T-cell immunoglobulin 3.
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